Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ121MR)

This product GTTS-WQ121MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ121MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8883MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ7609MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ16004MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ4585MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13472MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3959MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8604MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ3434MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AV-299
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW